Braveheart Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
52-week data presented at AHA Scientific Sessions 2026 further strengthen BHB-1893’s potential differentiation, with encouraging clinical activity and support for a highly simplified dosing regimen